DURHAM, N.C.--(BUSINESS WIRE)--Nov. 3, 2021--
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the third quarter 2021 and provide a business update on November 10, 2021.
Precision BioSciences also announced that Michael Amoroso, Chief Executive Officer will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference taking place November 15-17, 2021.
Details for the fireside chat are below:
Stifel 2021 Virtual Healthcare Conference
Date: Tuesday, November 16, 2021
Time: 1:20 PM ET
A live webcast of the fireside chat will be accessible on the Company’s website in the Investors section under Events & Presentations: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay of the webcast will be available for approximately 30 days.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005293/en/
Investor Contact:
Alex Kelly
Chief Financial Officer
Alex.Kelly@precisionbiosciences.com
Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Source: Precision BioSciences, Inc.
